Helen Kaulbach, MD
Endocrinology, Diabetes & Metabolism · Peabody, MANPI 1497751374
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,207 of the $43,455 with a category attached, or 74.1%. 34 manufacturers reported payments, led by Novo Nordisk at 30.1% of the total. Reporting peaked in 2019 at $31,436 and has fallen 99.4% since, to $181 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $105.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$13K
- Johnson & Johnson$12K
- AstraZeneca$9K
- Medtronic$5K
- Sanofi-aventis U.S. LLC$2K
- Lilly USA, LLC$407
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$32,20774%
- Travel & lodging$4,79911%
- Food & beverage$6,34615%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 202 | $13,092 |
| Johnson & Johnson | 45 | $12,089 |
| AstraZeneca(2 entities) | 28 | $9,220 |
| Medtronic(2 entities) | 41 | $4,668 |
| Sanofi-aventis U.S. LLC | 11 | $2,337 |
| Lilly USA, LLC | 17 | $407 |
| Amgen(2 entities) | 12 | $308 |
| Boehringer Ingelheim | 9 | $292 |
| AbbVie | 7 | $116 |
| Antares Pharma, Inc. | 5 | $107 |
| Insulet Corporation | 2 | $100 |
| Corcept Therapeutics | 1 | $75 |
| Amarin Pharma, Inc. | 1 | $75 |
| Radius Health, Inc. | 3 | $67 |
| Sanofi Pasteur Inc. | 5 | $64 |
| Merck | 3 | $46 |
| Pfizer | 3 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $36 |
| Eisai Inc. | 1 | $24 |
| Therapeuticsmd, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Vivus LLC | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Senseonics, Incorporated | 1 | $22 |
| Abbott | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Companion Medical, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Valeritas, Inc. | 1 | $11 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$11,467
- FARXIGA$8,667
- Tresiba$6,719
- Ozempic$3,753
- MINIMED 780G$2,932
- Minimed 670G System$560
- JARDIANCE$145
- EVENITY$115
- MOUNJARO$109
- Minimed 630G$102
How this compares
$43,455 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 253 | $458,767 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 134 | $352,362 |
| Tresiba Flextouch U-200Insulin Degludec | 145 | $184,903 |
| JardianceEmpagliflozin | 121 | $145,409 |
| MounjaroTirzepatide | 83 | $120,952 |
| FarxigaDapagliflozin Propanediol | 85 | $103,783 |
| TrulicityDulaglutide | 44 | $92,980 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $70,737 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $50,027 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $44,919 |
| RybelsusSemaglutide | 27 | $43,181 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $33,458 |
| JanuviaSitagliptin Phosphate | 24 | $27,709 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $21,352 |
| WegovySemaglutide | 15 | $17,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Wegovy, Novolog | $13,092 | $874,918441 claims |
| Lilly USA, LLCMounjaro, Trulicity | $407 | $213,932127 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $292 | $207,853166 claims |
| AstraZenecaFarxiga | $9,220 | $103,78385 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,337 | $70,73747 claims |
| MerckJanuvia | $46 | $27,70924 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $16 | $8,850981 claims |
| AbbVieSynthroid | $116 | $8,139180 claims |
| PfizerLevoxyl | $41 | $5,198108 claims |
| IBSA Pharma Inc.Tirosint | $19 | $1,79913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Peabody
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.